Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (5)	6/30/2000 9:06:46 AM
From: John McCarthy	Read Replies (1) \| Respond to of 278

Scott .... have you done any personal research on this drug .......? << Memantine is an orally active N-methyl-D-aspartate (NMDA) antagonist. Research indicates that NMDA-receptor antagonists have the potential to prevent the injury and death of neurons related to a variety of conditions, including neuropathic pain, Alzheimer's disease, Huntington's disease, and AIDS-related dementia. Memantine is the first NMDA receptor antagonist to show efficacy in Alzheimer's disease and vascular dementia << doing a search on alltheWeb.com will bring you a wealth of information .... regards, John McCarthy